Keyphrases
Dose-escalation Study
100%
Placental Growth Factor (PlGF)
100%
Advanced Solid Tumors
100%
Monoclonal Antibody
100%
Antitumor Activity
50%
Pharmacokinetic Effects
50%
Dose-limiting Toxicity
50%
Constipation
50%
Adverse Events
50%
Dyspnea
50%
Maximum Tolerated Dose
50%
Terminal Half-life
50%
Emboli
50%
Esophageal Squamous Cell Carcinoma
50%
Nausea
50%
Safety Profile
50%
Pancreatic Adenocarcinoma
50%
Pyrexia
50%
Lung
50%
Stable Disease
50%
Non-small Cell Lung Cancer (NSCLC)
50%
Serious Adverse Events
50%
Vascular Endothelial Growth Factor
50%
Pharmacokinetic Parameters
50%
Patient Demographics
50%
Anti-angiogenesis
50%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Monoclonal Antibody
100%
Adverse Event
100%
Vasculotropin
50%
Dyspnea
50%
Angiogenesis Inhibitor
50%
Diseases
50%
Nausea
50%
Fever
50%
Antitumor Activity
50%
Pharmacokinetic
50%
Pharmacokinetic Parameter
50%
Pancreas Adenocarcinoma
50%
Lung Embolism
50%
Non Small Cell Lung Cancer
50%
Constipation
50%
Maximum Tolerated Dose
50%
Placental Growth Factor
50%